|
EP1127882A1
(en)
|
2000-01-25 |
2001-08-29 |
Pfizer Products Inc. |
Tetrazole compounds as thyroid receptor ligands
|
|
US6664291B2
(en)
|
2000-03-31 |
2003-12-16 |
Pfizer, Inc. |
Malonamic acids and derivatives thereof as thyroid receptor ligands
|
|
FI107018B
(fi)
*
|
2000-04-06 |
2001-05-31 |
Ipsat Therapies Oy |
Dermatologinen käyttö ja valmiste
|
|
US8933236B2
(en)
|
2012-05-22 |
2015-01-13 |
Xenon Pharmaceuticals Inc. |
N-substituted benzamides and methods of use thereof
|
|
US6395784B1
(en)
*
|
2000-06-07 |
2002-05-28 |
Bristol-Myers Squibb Company |
Benzamide ligands for the thyroid receptor
|
|
DE10038007A1
(de)
*
|
2000-08-04 |
2002-02-14 |
Bayer Ag |
Neue Amino-und Amido-Diphenylether für Arzneimittel
|
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
|
GB0029100D0
(en)
*
|
2000-11-29 |
2001-01-10 |
Karobio Ab |
Compounds active at the glucocorticoid receptor
|
|
JP2004517851A
(ja)
|
2000-12-27 |
2004-06-17 |
バイエル アクチェンゲゼルシャフト |
甲状腺受容体のリガンドとしてのインドール誘導体
|
|
US7504435B2
(en)
|
2001-01-31 |
2009-03-17 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Method for stimulating weight loss and/or for lowering triglycerides in patients
|
|
KR20030072396A
(ko)
*
|
2001-02-08 |
2003-09-13 |
카로 바이오 아베 |
갑상선 수용체 리간드
|
|
US6777442B2
(en)
|
2001-03-12 |
2004-08-17 |
Bayer Aktiengesellschaft |
Diphenyl derivatives
|
|
DE10122443A1
(de)
*
|
2001-05-09 |
2002-11-14 |
Bayer Ag |
Amido-Diphenyl-Derivate
|
|
JP2005507381A
(ja)
|
2001-08-24 |
2005-03-17 |
カロ バイオ アクチェブラーグ |
心臓障害および代謝障害の治療のための主要環置換甲状腺受容体アンタゴニスト
|
|
GB0120691D0
(en)
*
|
2001-08-24 |
2001-10-17 |
Karobio Ab |
Novel Compounds
|
|
DE60208132T2
(de)
|
2001-09-26 |
2006-07-20 |
Pfizer Products Inc., Groton |
Indolcaroboxylsäure als Thyroidrezeptor-Liganden
|
|
EP1471049A4
(en)
|
2002-01-30 |
2006-08-16 |
Kissei Pharmaceutical |
NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
|
|
GB0208384D0
(en)
*
|
2002-04-11 |
2002-05-22 |
Karobio Ab |
Novel compounds
|
|
GB0215978D0
(en)
*
|
2002-07-10 |
2002-08-21 |
Karobio Ab |
Novel compounds
|
|
UA80437C2
(en)
*
|
2002-09-19 |
2007-09-25 |
Lilly Co Eli |
Diaryl ethers as opioid receptor antagonist
|
|
EP1477475A1
(en)
*
|
2003-05-16 |
2004-11-17 |
Procorde GmbH |
Compounds for use as a medicine increasing the contractility of a heart, a heart muscle or cells of a heart muscle
|
|
ITRM20030363A1
(it)
*
|
2003-07-24 |
2005-01-25 |
Fernando Goglia |
Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
|
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7674913B2
(en)
|
2003-11-12 |
2010-03-09 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
JP2007512359A
(ja)
|
2003-11-19 |
2007-05-17 |
メタバシス・セラピューティクス・インコーポレイテッド |
新規なリン含有甲状腺ホルモン様物質
|
|
US7618981B2
(en)
|
2004-05-06 |
2009-11-17 |
Cytokinetics, Inc. |
Imidazopyridinyl-benzamide anti-cancer agents
|
|
US7795448B2
(en)
|
2004-05-06 |
2010-09-14 |
Cytokinetics, Incorporated |
Imidazoyl-benzamide anti-cancer agents
|
|
US7504413B2
(en)
|
2004-05-06 |
2009-03-17 |
Cytokinetics, Inc. |
N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
EP2527337A1
(en)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
CA2606499C
(en)
|
2005-05-26 |
2017-06-13 |
Metabasis Therapeutics, Inc. |
Thyromimetics for the treatment of fatty liver diseases
|
|
TW200726765A
(en)
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
|
US7629342B2
(en)
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
|
US7317012B2
(en)
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
|
AU2006270914B2
(en)
|
2005-07-19 |
2011-01-20 |
Daiichi Sankyo Company, Limited |
Substituted propanamide derivative and pharmaceutical composition containing the same
|
|
JP4094660B1
(ja)
*
|
2005-08-10 |
2008-06-04 |
武田薬品工業株式会社 |
糖尿病治療剤
|
|
US7795436B2
(en)
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
|
AR056155A1
(es)
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
|
US7488725B2
(en)
|
2005-10-31 |
2009-02-10 |
Bristol-Myers Squibb Co. |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
|
TW200738621A
(en)
*
|
2005-11-28 |
2007-10-16 |
Astrazeneca Ab |
Chemical process
|
|
US7553836B2
(en)
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
|
ES2566481T3
(es)
|
2006-04-12 |
2016-04-13 |
Merck Sharp & Dohme Corp. |
Antagonistas del canal de calcio de tipo T de piridil amida
|
|
WO2007120083A1
(en)
*
|
2006-04-13 |
2007-10-25 |
Astrazeneca Ab |
The use of carboxamide derivatives in the manufacture of a medicament for the treatment of inflammatory, allergic and dermatological conditions
|
|
FR2900404B1
(fr)
*
|
2006-04-27 |
2008-07-18 |
Sod Conseils Rech Applic |
Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
|
|
WO2007132475A1
(en)
*
|
2006-05-15 |
2007-11-22 |
Cadila Healthcare Limited |
Selective tr-beta 1 agonist
|
|
WO2007139589A1
(en)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
|
RU2395489C2
(ru)
*
|
2006-11-01 |
2010-07-27 |
Институт элементоорганических соединений имени А.Н.Несмеянова Российской академии наук (ИНЭОС РАН) |
[f-18] меченная l-глютаминовая кислота, [f-18] меченный l-глютамин, их производные и их применение, а также способ их получения
|
|
EP2089355A2
(en)
|
2006-11-01 |
2009-08-19 |
Brystol-Myers Squibb Company |
Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
|
|
WO2008057857A1
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
|
EP2124873B1
(en)
*
|
2007-01-31 |
2016-01-06 |
Basf Se |
Cationic dyes
|
|
US8399518B2
(en)
|
2007-02-27 |
2013-03-19 |
University Of Arizona Office Of Technology Transfer |
Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome
|
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
|
WO2008130951A1
(en)
|
2007-04-17 |
2008-10-30 |
Bristol-Myers Squibb Company |
Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
|
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
|
CN101808995A
(zh)
|
2007-07-27 |
2010-08-18 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
|
CA2697551C
(en)
*
|
2007-09-20 |
2013-03-12 |
Irm Llc |
Piperidine derivatives as modulators of gpr119 activity
|
|
RU2010120671A
(ru)
*
|
2007-10-24 |
2011-11-27 |
Мерк Шарп Энд Домэ Корп. (Us) |
Гетероциклические фениламидные антагонисты кальциевых каналов т-типа
|
|
JP2011503081A
(ja)
|
2007-11-01 |
2011-01-27 |
ブリストル−マイヤーズ スクイブ カンパニー |
グルココルチコイド受容体、ＡＰ−１および／またはＮＦ−κＢ活性の調節剤として有用な非ステロイド性化合物、並びにその使用
|
|
GB0725214D0
(en)
*
|
2007-12-24 |
2008-02-06 |
Karobio Ab |
Pharmaceutical compounds
|
|
PE20091928A1
(es)
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
|
CA2741517A1
(en)
|
2008-10-27 |
2010-05-06 |
Cadila Healthcare Limited |
Thyroid receptor ligands
|
|
CA2742909C
(en)
|
2008-11-19 |
2017-12-19 |
Pola Chemical Industries Inc. |
Anti-wrinkle agents
|
|
WO2010086878A2
(en)
|
2009-01-09 |
2010-08-05 |
Cadila Healthcare Limited |
Thyroid receptor modulators
|
|
US20100256153A1
(en)
|
2009-03-27 |
2010-10-07 |
Bristol-Myers Squibb Company |
Methods for preventing or reducing risk of mortality
|
|
BRPI1015096A2
(pt)
*
|
2009-04-20 |
2016-05-03 |
Mitsubishi Tanabe Pharma Corp |
agonista de receptor beta de hormônio tireoideano
|
|
BR112012011726A2
(pt)
|
2009-11-13 |
2020-05-19 |
Bristol-Myers Squibb Company |
comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
|
|
CA2780938A1
(en)
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Reduced mass metformin formulations
|
|
WO2011060290A2
(en)
|
2009-11-13 |
2011-05-19 |
Bristol-Myer Squibb Company |
Immediate release tablet formulations
|
|
WO2011103126A1
(en)
*
|
2010-02-17 |
2011-08-25 |
Ampla Pharmaceuticals Inc. |
Treatment of metabolic syndrome with piperidine amides
|
|
WO2011130459A1
(en)
|
2010-04-14 |
2011-10-20 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
EP2560488B1
(en)
|
2010-04-23 |
2015-10-28 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
JP5830534B2
(ja)
|
2010-07-09 |
2015-12-09 |
ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ |
化合物
|
|
US8772343B2
(en)
|
2010-07-12 |
2014-07-08 |
Pfizer Limited |
Chemical compounds
|
|
ES2532357T3
(es)
|
2010-07-12 |
2015-03-26 |
Pfizer Limited |
Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
|
|
US9096500B2
(en)
|
2010-07-12 |
2015-08-04 |
Pfizer Limited |
Acyl sulfonamide compounds
|
|
CA2800971A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
|
WO2012007861A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
|
WO2013064984A1
(en)
|
2011-10-31 |
2013-05-10 |
Xenon Pharmaceuticals Inc. |
Biaryl ether sulfonamides and their use as therapeutic agents
|
|
JP6014154B2
(ja)
|
2011-10-31 |
2016-10-25 |
ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． |
ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
|
|
ES2593533T3
(es)
|
2011-12-15 |
2016-12-09 |
Pfizer Limited |
Derivados de sulfonamida
|
|
JP6067031B2
(ja)
*
|
2012-01-04 |
2017-01-25 |
ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ |
Ｎ−アミノスルホニルベンズアミド
|
|
CN102718718B
(zh)
*
|
2012-05-31 |
2014-09-24 |
绍兴文理学院 |
一种3,5-二溴-4-（5-苯并咪唑氧基）苯乙酸的制备方法
|
|
BR112015000187A2
(pt)
*
|
2012-07-06 |
2017-06-27 |
Genentech Inc |
benzamidas substituídas com n e métodos de uso das mesmas
|
|
US9586900B2
(en)
|
2012-09-05 |
2017-03-07 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
|
WO2014039412A1
(en)
|
2012-09-05 |
2014-03-13 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
|
KR20150131233A
(ko)
|
2013-03-14 |
2015-11-24 |
제넨테크, 인크. |
치환된 트리아졸로피리딘 및 이의 사용 방법
|
|
US9493429B2
(en)
|
2013-03-15 |
2016-11-15 |
Genentech, Inc. |
Substituted benzoxazoles and methods of use thereof
|
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
|
CR20160296A
(es)
|
2013-11-27 |
2016-09-20 |
Genentech Inc |
Benzamidas sustituidas y métodos para usarlas
|
|
CN103709094B
(zh)
*
|
2014-01-07 |
2016-04-06 |
厦门大学 |
4-苯氧基苯甲酰胺类化合物及其制备方法和应用
|
|
WO2016007534A1
(en)
|
2014-07-07 |
2016-01-14 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
EP3297989A1
(en)
|
2015-05-22 |
2018-03-28 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
CN108137477A
(zh)
|
2015-08-27 |
2018-06-08 |
基因泰克公司 |
治疗化合物及其使用方法
|
|
CN108290881B
(zh)
|
2015-09-28 |
2021-12-07 |
健泰科生物技术公司 |
治疗性化合物和其使用方法
|
|
EP3380466A1
(en)
|
2015-11-25 |
2018-10-03 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
US10766858B2
(en)
|
2016-03-30 |
2020-09-08 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
ES2940611T3
(es)
*
|
2016-04-18 |
2023-05-09 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
|
|
WO2018032012A1
(en)
*
|
2016-08-12 |
2018-02-15 |
Oregon Health & Science University |
Amide compounds, pharmaceutical compositions thereof, and methods of using the same
|
|
MX388175B
(es)
|
2016-10-17 |
2025-03-19 |
Genentech Inc |
Compuestos terapéuticos y métodos para utilizarlos
|
|
WO2018094265A2
(en)
|
2016-11-21 |
2018-05-24 |
Viking Therapeutics, Inc. |
Method of treating glycogen storage disease
|
|
CN106588690B
(zh)
*
|
2016-12-19 |
2019-06-04 |
广西中医药大学 |
毛鸡骨草甲素Abrusamide的制备方法
|
|
EP3601273B1
(en)
|
2017-03-24 |
2021-12-01 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
|
CN110996966A
(zh)
|
2017-06-05 |
2020-04-10 |
维京治疗公司 |
用于治疗纤维化的组合物
|
|
EP3683306A4
(en)
|
2017-09-14 |
2021-06-09 |
Riken |
METHOD FOR MANUFACTURING RETINAGE TISSUE
|
|
JP7157804B2
(ja)
*
|
2017-10-17 |
2022-10-20 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する病態を治療するためのスルホンアミド及びその組成物
|
|
CN111518770B
(zh)
|
2017-12-19 |
2023-01-06 |
北京吉源生物科技有限公司 |
一种表达glp1和fgf21的干细胞及其用途
|
|
CN112041313A
(zh)
|
2018-02-26 |
2020-12-04 |
基因泰克公司 |
吡啶-磺酰胺化合物及其针对疼痛和相关疾患的用途
|
|
KR20200138283A
(ko)
|
2018-03-22 |
2020-12-09 |
바이킹 테라퓨틱스 인코포레이티드 |
결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
|
|
JP2021519788A
(ja)
|
2018-03-30 |
2021-08-12 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
MA53175A
(fr)
|
2018-07-19 |
2021-05-26 |
Astrazeneca Ab |
Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
|
|
WO2020117962A1
(en)
|
2018-12-05 |
2020-06-11 |
Viking Therapeutics, Inc. |
Compositions for the treatment of fibrosis and inflammation
|
|
JP2022513449A
(ja)
|
2018-12-12 |
2022-02-08 |
オートバーン セラピューティクス，インク． |
新規な甲状腺模倣物
|
|
WO2020180624A1
(en)
|
2019-03-01 |
2020-09-10 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
|
MY206063A
(en)
|
2019-03-13 |
2024-11-27 |
Riken |
Method for evaluating quality of transplant neural retina, and transplant neural retina sheet
|
|
WO2021026179A1
(en)
*
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
EP4065098A4
(en)
|
2019-11-29 |
2023-12-27 |
Autobahn Therapeutics, Inc. |
NOVEL THYROMIMETICS
|
|
WO2022054924A1
(ja)
|
2020-09-11 |
2022-03-17 |
大日本住友製薬株式会社 |
移植用組織のための媒体
|
|
JPWO2022054925A1
(enExample)
|
2020-09-11 |
2022-03-17 |
|
|
|
JPWO2023090427A1
(enExample)
|
2021-11-19 |
2023-05-25 |
|
|
|
US12377058B1
(en)
|
2024-04-29 |
2025-08-05 |
Imam Mohammad Ibn Saud Islamic University |
Method for inhibiting proliferation of cancer cells
|